Ublituximab for Multiple Sclerosis

"As a Phase 2 trial, Ublituximab is believed to have some safety data but has yet to be proven effective in clinical trials. Therefore, it received an assessment of 2 on our scale."

"Data on clinicaltrials.gov affirms that, since its inception in June 2017 and last update November 2021, this medical trial is not actively recruiting patients. However, there are 560 other trials which are currently accepting participants for their study."

"In 2015, the initial ublituximab trials took place at TG Therapeutics Investigational Trial Site. Currently there have been 9 finished studies and 11 ongoing ones; many of which are being administered in Pasadena, California."

"To qualify for this medical trial, prospective participants must be aged 18 or higher and no older than 55."

"To qualify for this medical trial, potential participants must have been diagnosed with multiple sclerosis and be in the age range of 18 to 55. Currently, 48 people are being sought after as study enrollees."

"This investigation is taking place in 8 distinct medical centres, including Pasadena, Lexington and San Antonio. It may be prudent to choose the closest site available when enrolling so as to reduce travel needs."

"Since its initial trial in 2015, sponsored by TG Therapeutics Inc., Ublituximab has been successful and achieved Phase 3 drug approval. Nowadays, 11 active clinical trials for the medication are ongoing within 133 cities across 13 countries."

"This clinical trial has closed for recruitment. It had been posted on June 1st 2017 and the latest update was November 21st 2022. If you are in search of alternative trials, there are presently 549 recruiting studies investigating multiple sclerosis and 11 accepting patients that require Ublituximab treatment."